The Power of Vaccines: ‘getting to zero’ for HIV and TB Understanding the R&D funding landscape

Roni Liyanage Senior Policy Analyst rliyanage@policycures.org

Outline

• About Policy Cures • About G-FINDER • Neglected disease R&D funding • Vaccine R&D funding • HIV & TB vaccine funding

• Key messages

About Policy Cures

Innovative ideas and accurate analysis to accelerate development and uptake of new drugs, vaccines, diagnostics and other products for neglected diseases of the developing world

<INSERT PICTURE>

About G-FINDER

WHO/MALI

• An annual funding survey (2007, 2008, 2009, 2010) – 31 neglected diseases

– 134 product areas

– All R&D stages

• Over 8,000 entries per year – Data from 54 countries

– Data from 240 organisations

• Funded by the Bill & Melinda Gates Foundation

Neglected Disease R&D Funding

Total Neglected Disease R&D funding

$3,063 million invested in neglected disease R&D in 2010

↓$109m (-3.5%)

$0

$500

$1,000

$1,500

$2,000

$2,500

$3,000

$3,500

2007 2008 2009 2010

Mill

ion

s

HIV/AIDS

$1.07 BILLION Total spend on HIV/AIDS R&D in 2010

35% of Global ND R&D funding

HIV & TB R&D funding

TB

$575.4 MILLION Total spend on TB R&D in 2010

18.8% of Global ND R&D funding

$-

$200

$400

$600

$800

$1,000

$1,200

2007 2008 2009 2010

Mill

ion

s

HIV

TB

Vaccine R&D Funding

Vaccine R&D funding

$0

$200

$400

$600

$800

$1,000

$1,200

$1,400

2007 2008 2009 2010

Mill

ion

s

Public funding Industry funding Philanthropic funding

62% Public funding

20% Industry funding

17% Philanthropic funding

Vaccine R&D funding

Other 4% Bacterial

Pneumonia & Meningitis 7%

Diarrhoeal diseases 7%

Malaria 8%

TB 9%

Dengue 10%

HIV/AIDS 55%

Top funders of neglected disease vaccine R&D, 2010

1 NIH $509m 2 Pharmaceutical Industry $223m

3 Bill & Melinda Gates Foundation $176m 4 U S D e p a r t m e n t o f D e f e n s e ( D O D ) $ 4 3 m

5 US Agency for International Development (USAID) $33m

6 UK Department for International Development (DFID) $30m

7 E u r o p e a n C o m m i s s i o n : R e s e a r c h D i r e c t o r a t e - G e n e r a l $ 2 7 m

HIV & TB Vaccine R&D Funding

HIV/AIDS

$589.9 million Total spend on HIV Vaccine R&D in 2010

HIV & TB Vaccine R&D funding 2007-2010

TB

$81.9 MILLION Total spend on TB Vaccine R&D in 2010

$-

$100

$200

$300

$400

$500

$600

$700

2007 2008 2009 2010

Mill

ion

s

HIV

TB

HIV Vaccine R&D funding – by funder type 2010

Public funding

86%

Philanthropic

funding 12%

Industry funding

2%

Top funders HIV Vaccine R&D, 2010

1 US NIH $414m

2 Bill & Melinda Gates Foundation

$65m

3 USAID $27m

4 US DoD $25m

5 Industry $21m

6 UK DFID $14m

7 European Commission $10m

8 The Wellcome Trust $4m

TB Vaccine R&D funding – by funder type, 2010

Public funding 49%

Philanthropic funding

40%

Industry funding

9%

Other 2% Top funders TB Vaccine R&D, 2010

1 Bill & Melinda Gates Foundation $30m

2 Industry $17m

3 US NIH $15m

4 UK DFID $10m

5 Health Protection Agency $4m

6 European Commission

$4m

of public funding for HIV vaccine R&D came from Science and Technology funding agencies in 2010 of public funding for TB vaccine R&D came from Science and Technology funding agencies in 2010

Science & Technology Vs Aid funding

90%

66%

European public funding of HIV Vaccine R&D

↓$15.8m (-29%) in 2010

$16.7m (-22%) in 2010 From UK

$10.8m (-36%) in 2010 From EC

$-

$10

$20

$30

$40

$50

$60

$70

2007 2008 2009 2010

Mill

ion

s

Norway

Switzerland

France

Sweden

Denmark

Ireland

Netherlands

European Commission

UK

European public funding of TB Vaccine R&D

↓$5.9m (-20%) in 2010

$14.3m (up 21%) in 2010 From UK

$4.0m (-45%) in 2010 From EC

$-

$5

$10

$15

$20

$25

$30

$35

2007 2008 2009 2010

Mill

ion

s

Spain

Sweden

Denmark

Switzerland

Netherlands

European Commission

UK

The HIV and TB vaccine portfolios

Several products moving into expensive late-stage clinical trials

0

5

10

15

20

25

30

HIV Vaccines TB Vaccine

Preclinical

Phase I

Phase II

Phase III

Key messages

Vaccine R&D funding for neglected diseases

• Funding is highly concentrated • Mostly comes from:

• US funders • Public sector • Science and technology budgets

• Funding cuts at a time when several

promising products are entering late stage development

Vaccine R&D funding for neglected diseases

- R&D pipelines need reliable long-term funding

- Financial pressures mean smarter funding will be needed: - Outcome driven and flexible - Aligned with product and portfolio developments - Coordinated - Targeted to deliver the highest health impact

It took a long time and a lot of effort to restart neglected disease vaccine R&D but it is under threat –

The time to act is NOW